The Food and Drug Administration (FDA) in the United States has approved a New Drug Investigation Request (IND) for human trials proposed by biotechnology company ANANDA Scientific. The trials are expected to test their investigational drug Nantheia ATL5 for its effectiveness in treating opioid dependence.
Nantheia is a patented CBD delivery system designed by ANANDA to increase the bioavailability of CBD in the body. Ananda’s website says: “The importance of being able to make CBD water soluble and efficiently, predictably and economically pass it through the bloodstream cannot be overstated. It is crucial for CBD to realize its deep therapeutic potential. The problem has been solved in a distinctive way by ANANDA Scientific through its unique and patented “Liquid StructureTM” technology. It turns CBD (along with other substances derived from problematic plants) into exceptional nutraceuticals and pharmaceuticals that really work.“
The United States is currently experiencing a record number of opioid-related deaths. Data collected by the Centers for Disease Control and Prevention (CDC) at the end of last year showed that more than 53,000 opioid-related deaths have been reported in 2021. Commenting on the approval of the trials ANANDA CEO Sohail Zaida said “This is the fourth IND approval for our investigational drug Nantheia product range, and this further strengthens our vision to develop CBD as a therapeutic for a number of key indications. This clinical study at UCLA is an important component of our clinical development efforts focused on opioid dependence, where non-addictive therapy is a significant unmet need. We are excited to be working with the UCLA team and look forward to seeing this essay progress. “
In A declaration published on January 4, ANANDA said the trials would be led by Dr Edythe London and Dr Richard de la Garza from the Jane and Terry Semel Institute at the David Geffen School of Medicine at UCLA. Funding for the trial was provided by the National Institute of Drug Abuse (NIMA).
Dr London said: “IND approval for this important clinical trial is a key milestone for our ongoing research into alternative therapies for opioid use disorder and reversal of the effects of opioid use. opioid epidemic. “
Currently, the only FDA approved herbal medicine containing CBD is Epidiolex, which is produced in the UK by GW Pharmaceuticals. GW was bought under a massive $ 7.2 billion deal early last year. Epidiolex treats two rare forms of epilepsy in children over two years of age, Lennox-Gastaut syndrome and Dravet syndrome.